Dianthus Therapeutics, Inc.
DNTH
$24.33
$0.923.93%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -83.40% | -12.29% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -83.40% | -12.29% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -83.40% | -12.29% | |||
| SG&A Expenses | 20.88% | 7.44% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 2.27% | 3.30% | |||
| Operating Income | -5.27% | -3.95% | |||
| Income Before Tax | -7.18% | -3.77% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -7.18% | -3.77% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -7.18% | -3.77% | |||
| EBIT | -5.27% | -3.95% | |||
| EBITDA | -5.27% | -3.95% | |||
| EPS Basic | -7.08% | -1.56% | |||
| Normalized Basic EPS | -4.23% | -8.70% | |||
| EPS Diluted | -7.08% | -1.56% | |||
| Normalized Diluted EPS | -4.23% | -8.70% | |||
| Average Basic Shares Outstanding | 0.09% | 2.16% | |||
| Average Diluted Shares Outstanding | 0.09% | 2.16% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||